PMCC PMCC

Search tips
Search criteria

Advanced
Results 1-5 (5)
 

Clipboard (0)
None

Select a Filter Below

Journals
Year of Publication
1.  The AQP1 mutation c.601delG causes the Co-negative phenotype in four patients belonging to the Romani (Gypsy) ethnic group 
Blood Transfusion  2014;12(1):73-77.
Background
The Colton blood group antigens Coa, Cob and Co3 are encoded by the AQP1 gene which produces a water channel forming integral protein. The extremely rare Co-deficiency enables immunisation against the Co3 isoantigen.
Materials and methods
Four patients from different regions of Europe who belong to the ethnic minority of Romani (Gypsy) presented with irregular antibodies against a high frequency red blood cell antigen. Positive cross-matches with all red blood cells tested were reported. An Anti-Co3 antibody was identified as the cause of incompatibility in the four cases. The genetic background was determined by polymerase chain reaction typing with sequence-specific primers and by DNA sequencing.
Results
The Co(a−b−) phenotype was confirmed in the four patients despite the fact that genotyping revealed the CO*01 allele of the AQP1 gene. A homozygous AQP1 c.601delG mutation, leading to a frame shift and producing a premature stop in the next codon, was responsible for the Co-negative phenotype in all four cases. While one patient was successfully transfused with blood from his sibling with the identical mutation, another case, a baby affected by haemolytic disease of the newborn, recovered without transfusion.
Discussion
Despite the difficulties in undertaking a population study to determine the prevalence of this AQP1 c.601delG allele in the ethnic minority of Romani, the observations described in this report clearly suggest an accumulation of this mutation, which causes the Co(a−b−) phenotype, in Romani (Gypsy) patients. Further studies are necessary to prove such an accumulation.
doi:10.2450/2013.0067-13
PMCID: PMC3926733  PMID: 24333057
red blood cells; AQP1; Colton blood group; DNA sequencing; Romani (Gypsy)
2.  Female donors and transfusion-related acute lung injury: A case-referent study from the International TRALI Unisex Research Group 
Transfusion  2010;50(11):2447-2454.
BACKGROUND
Although quantitative evidence is lacking, it is generally believed that the majority of cases of transfusion-related acute lung injury (TRALI) are caused by female blood donors. We aimed to examine the relation between female donors and the occurrence of TRALI.
STUDY DESIGN AND METHODS
We performed an international, multicenter case-referent study. TRALI patients who were diagnosed clinically, independent of serology or donor sex, and had received transfusions either only from male donors or only from female donors (unisex cases) were selected. The observed sex distribution among the donors of these TRALI patients was compared to the expected sex distribution, based on the relevant donor populations.
RESULTS
Eighty-three clinical TRALI cases were included; 67 cases received only red blood cells (RBCs), 13 only plasma-rich products, and three both. Among RBC recipients the relative risk (RR) of TRALI after a transfusion from a female donor was 1.2 (95% confidence interval [CI], 0.69–2.1) and among plasma-rich product recipients the RR was 19 (95% CI, 1.9–191). The p value for the difference between RBCs and plasma was 0.023.
CONCLUSION
Our data support the notion that plasma from female donors is associated with an increased risk of TRALI, while RBCs from female donors are not.
doi:10.1111/j.1537-2995.2010.02715.x
PMCID: PMC3740332  PMID: 20529001
3.  A simple approach to confirm the presence of anti-D in sera with presumed anti-D+C specificity 
Blood Transfusion  2013;11(3):449-451.
doi:10.2450/2012.0192-12
PMCID: PMC3729138  PMID: 23399363
RhD alloimmunisation; antibody investigation; anti-D and anti-C specificity; anti-G
5.  The Bloodgen Project of the European Union, 2003–2009 
Summary
The Bloodgen project was funded by the European Commission between 2003 and 2006, and involved academic blood centres, universities, and Progenika Biopharma S.A., a commercial supplier of genotyping platforms that incorporate glass arrays. The project has led to the development of a commercially available product, BLOODchip, that can be used to comprehensively genotype an individual for all clinically significant blood groups. The intention of making this system available is that blood services and perhaps even hospital blood banks would be able to obtain extended information concerning the blood group of routine blood donors and vulnerable patient groups. This may be of significant use in the current management of multi-transfused patients who become alloimmunised due to incomplete matching of blood groups. In the future it can be envisaged that better matching of donor-patient blood could be achieved by comprehensive genotyping of every blood donor, especially regular ones. This situation could even be extended to genotyping every individual at birth, which may prove to have significant long-term health economic benefits as it may be coupled with detection of inborn errors of metabolism.
doi:10.1159/000218192
PMCID: PMC2980524  PMID: 21113258
BLOODchip; Blood groups; Blood group antigens

Results 1-5 (5)